Toggle Main Menu Toggle Search

Open Access padlockePrints


Lookup NU author(s): Dr Miranda Patterson, Dr Yvette DrewORCiD, Professor Nicola CurtinORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© Springer Science+Business Media New York 2017. All rights reserved. PARP enzymes synthese poly(ADP-ribose) (PAR) using nicotinamide adenine dinucleotide (NAD+) as a substrate. PARP-1 is the most extensively studied of a family of PARP enzymes. It is a highly abundant nuclear protein that is activated by DNA breaks and facilitates their repair. PARP inhibitors (PARPis), originally designed to enhance the activity of DNA damaging chemo- and radiotherapy can exploit defects in homologous recombination DNA repair (HRR) by a process termed synthetic lethality. This potential for tumour-selective non-toxic therapy with PARPi has proved the impetus to progress the development of these compounds further.

Publication metadata

Author(s): Patterson MJ, Drew Y, Curtin NJ

Publication type: Book Chapter

Publication status: Published

Book Title: Cancer Therapeutic Targets

Year: 2017

Pages: 913-934

Online publication date: 09/04/2017

Acceptance date: 02/04/2016

Publisher: Springer

Place Published: New York


DOI: 10.1007/978-1-4419-0717-2_53

Library holdings: Search Newcastle University Library for this item

ISBN: 9781441907172